# Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

> **NCT06009393** · PHASE2 · COMPLETED · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 26 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** SHR-1918

## Key facts

- **NCT ID:** NCT06009393
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-22
- **Primary completion:** 2024-06-29
- **Final completion:** 2024-08-23
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06009393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06009393, "Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06009393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*